Payment overview · 2025
General Payments
$1,368.81
97 reported records · 18 companies
Healthcare provider profile · identity verified
Miranda R Hernly, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · AUSTIN, IN · NPI 1831815216
Verified facts
What the public records show
CMS Open Payments records show Miranda R Hernly, APRN received $1,368.81 in general payments during 2025 across 97 reported records.
Alkermes, Inc. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Mounjaro, Ozempic, Quviviq, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
IDORSIA PHARMACEUTICALS US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUVIVIQ as an associated drug or biological on 2281 records involving 1911 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Quviviq by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $292.41 | 21.4% | 29 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $262.29 | 19.2% | 22 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $190.09 | 13.9% | 14 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $103.62 | 7.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.39 | 5.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.85 | 4.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.20 | 3.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.17 | 3.7% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $47.25 | 3.5% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $39.90 | 2.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $37.23 | 2.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.84 | 2.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.95 | 2.0% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $21.06 | 1.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.30 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.55 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.90 | 1.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $14.81 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,368.81 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $234.26 | 25 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $190.09 | 14 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $115.26 | 13 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $103.62 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $68.72 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.62 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.85 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.44 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.44 | 3 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $58.15 | 4 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $54.92 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $53.20 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $47.25 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $44.08 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $39.90 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $38.33 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Quviviq quviviq |
2025 | Quviviq | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| IDORSIA PHARMACEUTICALS US INC Exact reporting entity; no affiliate inference |
2025 | QUVIVIQ open payments reported associated product |
CMS Open Payments — General Payments 2281 supporting records · 1911 recipient NPIs · example record 1243392023 |
Quviviq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 122 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 103 | 26 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 98 | suppressed |
| Lisinopril | Lisinopril | 96 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 86 | 24 |
| Losartan Potassium | Losartan Potassium | 86 | 18 |
| Meloxicam | Meloxicam | 85 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 16 |
| Buspirone Hcl | Buspirone Hcl | 64 | 13 |
| Trazodone Hcl | Trazodone Hcl | 62 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 60 | 16 |
| Furosemide | Furosemide | 58 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 58 | 16 |
| Metformin Hcl | Metformin Hcl | 55 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Omeprazole | Omeprazole | 48 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 37 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Simvastatin | Simvastatin | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 20 |
| Caplyta | Lumateperone Tosylate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,368.81 · 97 records | Alkermes, Inc. | ABILIFY ASIMTUFII, ARISTADA, CAPLYTA, Cologuard Collection Kit, DOVATO, FANAPT, Kerendia, Korlym, LYBALVI, MAVYRET, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Quviviq, REXULTI, Rybelsus, SUBLOCADE, TRINTELLIX, UBRELVY, VIBERZI, VIVITROL, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error